Abstract
To the Editor: Schulman et al. (Feb. 21 issue)1 report the results of the RE-MEDY and RE-SONATE trials. In these trials, there was a significantly higher number of acute coronary events in patients who received dabigatran than in patients who received warfarin and the same number of acute coronary events in patients who received dabigatran and in those who received placebo. As the authors noted, the increased risk of acute coronary syndromes with dabigatran was previously observed in the landmark Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial,2 and it was subsequently reported in a meta-analysis of seven trials that . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
